These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 29536348)
1. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency. Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348 [TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455 [TBL] [Abstract][Full Text] [Related]
3. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365 [TBL] [Abstract][Full Text] [Related]
4. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610 [TBL] [Abstract][Full Text] [Related]
5. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007 [TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094 [TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Lo YL; Liu Y; Tsai JC Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284 [TBL] [Abstract][Full Text] [Related]
8. Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. Pan Q; Zhang J; Li X; Han X; Zou Q; Zhang P; Luo Y; Jin Y Pharmazie; 2019 Oct; 74(10):577-582. PubMed ID: 31685080 [TBL] [Abstract][Full Text] [Related]
9. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833 [TBL] [Abstract][Full Text] [Related]
10. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868 [TBL] [Abstract][Full Text] [Related]
11. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes]. Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658 [TBL] [Abstract][Full Text] [Related]
12. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer. Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519 [TBL] [Abstract][Full Text] [Related]
13. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. Gandhi R; Khatri N; Baradia D; Vhora I; Misra A Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675 [TBL] [Abstract][Full Text] [Related]
14. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
15. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy. Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248 [TBL] [Abstract][Full Text] [Related]
18. Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies. Gao F; Li L; Zhang H; Yang W; Chen H; Zhou J; Zhou Z; Wang Y; Cai Y; Li X; Liu L; Zhang Q Int J Pharm; 2010 Jun; 392(1-2):254-60. PubMed ID: 20347028 [TBL] [Abstract][Full Text] [Related]
19. Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. Tariq M; Alam MA; Singh AT; Iqbal Z; Panda AK; Talegaonkar S Colloids Surf B Biointerfaces; 2015 Apr; 128():448-456. PubMed ID: 25769281 [TBL] [Abstract][Full Text] [Related]
20. Polysialic acid and pluronic F127 mixed polymeric micelles of docetaxel as new approach for enhanced antitumor efficacy. Zhang T; Zhou S; Liu Y; Luo X; Di D; Song Y; Liu X; Deng Y Drug Dev Ind Pharm; 2017 Nov; 43(11):1827-1835. PubMed ID: 28678638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]